glp-1 and menopause GLP-1s, Obesity, Menopause: Benefits and Risks GLP-1s and Hormone Therapy: A

This morning, Ro dropped what is now the lowest entry point for an FDA approved GLP-1

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

While nothing works exactlylike Ozempic, there are evidence-backed, natural options that can help regulate blood sugar, supp

Lilly is studying retatrutide across obesity, type 2 diabetes, cardiovascular risk, and related conditions

WHO GLP-1 Treatments: The World Health Organization has issued new guidelines endorsing GLP-1 agonists as essential treatments for obesity, highlighting the urgent need for action against the rising global obesity epidemic affecting over one billion people and posing serious health risks.

Ascletis ASC35, a once-monthly GLP-1/GIP peptide using a self-assembling lipid depot, cleared FDA IND for Phase 1 head-to-head vs weekly tirzepatide June 23.